Our industry’s response to COVID-19 defied the conventional wisdom that it takes years to deliver new drugs. Makers of monoclonal antibodies led the pack, most notably Regeneron (NSDQ:REGN), which manufactured the 8-g, two-antibody cocktail administered to then-President Donald Trump last fall. Eli Lilly (NYSE:LLY) and Vir Biotechnology (NSDQ:VIR) pulled off similar feats. Prior speed records…
XPOVIO offers promise for multiple myeloma
FDA has indicated Karyopharm Therapeutics‘ nuclear export inhibitor Xpovio for relapsed or refractory multiple myeloma (RRMM). The indication covers its use in conjunction with the steroid dexamethasone. Patients receiving the drug should receive at least four previous therapies. Furthermore, the indication covers patients with myeloma that is refractory to at least two proteasome inhibitors, two immunomodulatory agents and…